ArticleThoracic cancer2017
Female breast cancer incidence and mortality in China, 2013.
Article in Thoracic cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- APC gene promoter aberrant methylation in serum as a biomarker for breast cancer diagnosis: A meta-analysis.Thoracic cancer · 2018Pooled it
- Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.Chinese medical journal · 2025Trial
- Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.PloS one · 2018Trial
- PD‑L1 mediates triple‑negative breast cancer evolution via the regulation of TAM/M2 polarization.International journal of oncology · 2022Article
- Breast Cancer Survival in Eastern Region of Ghana.Frontiers in public health · 2022Article
- Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.Journal of cancer research and clinical oncology · 2021Article
- MicroRNA-638 inhibits the progression of breast cancer through targeting HOXA9 and suppressing Wnt/β-cadherin pathway.World journal of surgical oncology · 2021Article
- Early SUVQuantitative imaging in medicine and surgery · 2021Article
- Nomogram based on radiomics analysis of primary breast cancer ultrasound images: prediction of axillary lymph node tumor burden in patients.European radiology · 2021Article
- Trends in breast cancer incidence in Ho Chi Minh City 1996-2015: A registry-based study.PloS one · 2021Article
- The use of trastuzumab affected by health insurance policy in Jiangsu Province of China.Translational cancer research · 2021Article
- Knockdown of LINC00504 Inhibits the Proliferation and Invasion of Breast Cancer via the Downregulation of miR-140-5p.OncoTargets and therapy · 2021Article
- LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis.Bioscience reports · 2020Observational
- Treatment decision-making, family influences, and cultural influences of Chinese breast cancer survivors: a qualitative study using an expressive writing method.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- miR-320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway.Oncology letters · 2020Article
- miR-200b regulates breast cancer cell proliferation and invasion by targeting radixin.Experimental and therapeutic medicine · 2020Article
- Trends and Projections in Breast Cancer Mortality among four Asian countries (1990-2017): Evidence from five Stochastic Mortality Models.Scientific reports · 2020Article
- MicroRNA-383-5p acts as a potential prognostic biomarker and an inhibitor of tumor cell proliferation, migration, and invasion in breast cancer.Cancer biomarkers : section A of Disease markers · 2020Article
- Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.American journal of cancer research · 2020Review
- Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China.Journal of Cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most common cancer among women. Population-based cancer registration data from the National Central Cancer Registry were used to analyze and evaluate the incidence and mortality rates in China in 2013, providing scientific information for cancer prevention and control.
methodsPooled data were stratified by area (urban/rural), gender, and age group. National new cases and deaths were estimated using age-specific rates and the corresponding population in 2013. The Chinese population in 2000 and Segi's world population were used to calculate age-standardized rates.
resultsThe estimated number of new breast cancer cases was about 278 800 in China in 2013. The crude incidence, age-standardized rate of incidence by Chinese standard population, and age-standardized rate of incidence by world standard population were 42.02/100 000, 30.41/100 000, and 28.42/100 000, respectively. The estimated number of breast cancer deaths was about 64 600 in China in 2013. The crude mortality, age-standardized rate of mortality by Chinese standard population, and age-standardized rate of mortality by world standard population were 9.74/100 000, 6.54/100 000, and 6.34/100 000, respectively. Both incidence and mortality were higher in urban than in rural areas. Age-specific breast cancer incidence significantly increased with age, particularly after age 20, and peaked at 50-55 years, while age-specific mortality increased rapidly after 25 years, peaking at 85+ years.
conclusionsBreast cancer is the most common cancer in Chinese women, especially women in urban areas. Comprehensive measures are needed to reduce the heavy burden of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.